dˌɪsɹɪɡjʊlˈeɪʃən ʌvðə tˌiːˌɑːɹkˈeɪ bˈiː slˈæʃ bˌiːdˌiːˌɛnˈɛf pˈæθweɪ hˈæzbiːn ˈɪmplᵻkˌeɪɾᵻd ɪn ˈʌðɚ nˌʊɹɹəlˈɑːdʒɪkəl ænd nˈʊɹɹoʊddʒˌɛnɚɹətˌɪv kəndˈɪʃənz, ɪŋklˈuːdɪŋ stɹˈoʊk, hˈʌntɪŋtənz dɪzˈiːz, pˈɑːɹkɪnsənz dɪzˈiːz, ˌæmɪətɹˈoʊfɪk lˈæɾɚɹəl ʃləɹˈoʊsɪs ænd stɹˈɛsɹᵻlˈeɪɾᵻd dɪsˈoːɹdɚz.noʊtˈɑːɹɹəz ænd vˈændɛn bˈuːs, tˈuː θˈaʊzənd twˈɛnti; pɹˈædhən ˈɛt ˈæl., tˈuː θˈaʊzənd nˈaɪntiːn; tˈɛdʒɛdə ænd dˈiːɐsɡˈɛɹə, tˈuː θˈaʊzənd sˈɛvəntˌiːn.
Dysregulation of the TrkB/BDNF pathway has been implicated in other neurological and neurodegenerative conditions, including stroke, Huntington’s Disease, Parkinson’s Disease, Amyotrophic lateral schlerosis and stress-related disorders.(Notaras and van den Buuse, 2020; Pradhan et al., 2019; Tejeda and Díaz-Guerra, 2017).